摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-(4-methylpiperazin-1-yl)benzene-1,2-diamine | 319474-52-7

中文名称
——
中文别名
——
英文名称
3-(4-methylpiperazin-1-yl)benzene-1,2-diamine
英文别名
——
3-(4-methylpiperazin-1-yl)benzene-1,2-diamine化学式
CAS
319474-52-7
化学式
C11H18N4
mdl
MFCD24393404
分子量
206.291
InChiKey
BSHKOIWZXZNENI-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    387.5±42.0 °C(Predicted)
  • 密度:
    1.163±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    0.5
  • 重原子数:
    15
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.454
  • 拓扑面积:
    58.5
  • 氢给体数:
    2
  • 氢受体数:
    4

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    3-(4-methylpiperazin-1-yl)benzene-1,2-diamine 在 palladium 10% on activated carbon 氢气双(2-氧代-3-恶唑烷基)次磷酰氯N,N-二异丙基乙胺碳酸氢钠溶剂黄146 作用下, 以 甲醇乙腈 为溶剂, 20.0 ℃ 、344.75 kPa 条件下, 反应 5.0h, 以56%的产率得到(4aR,10bS)-1-{[4-(4-methyl-1-piperazinyl)-1H-benzimidazol-2-yl]methyl}-1,2,3,4,4a,5,6,10b-octahydro-1,10-phenanthroline
    参考文献:
    名称:
    WO2006/96444
    摘要:
    公开号:
  • 作为产物:
    描述:
    参考文献:
    名称:
    发现 1-(5-(1H-benzo[d]imidazole-2-yl)-2,4-dimethyl-1H-pyrrol-3-yl)ethan-1-one 衍生物作为新型有效溴结构域和末端外(BET) 具有抗癌功效的抑制剂
    摘要:
    作为表观遗传阅读器,溴结构域和末端外结构域 (BET) 家族蛋白与组蛋白中的乙酰化赖氨酸残基结合并募集蛋白质复合物以促进转录起始和延伸。通过小分子抑制剂抑制 BET 溴结构域已成为一种有前途的癌症治疗策略。在这里,我们描述了我们为发现一系列新的 1-(5-(1 H -benzo[ d ]imidazole-2-yl)-2,4-dimethyl-1 H -pyrrol-3-yl)ethan 所做的努力-1-one 衍生物作为 BET 抑制剂。密集的结构修饰导致化合物35f被鉴定为对 BET 家族蛋白具有选择性的最活跃的 BET BRD4 抑制剂。进一步的生物学研究表明,化合物35f通过降低c-Myc等细胞周期和细胞凋亡相关蛋白的表达,使细胞周期停滞在G 0 /G 1期,诱导细胞凋亡。更重要的是,化合物35f在 MV4-11 小鼠异种移植模型中显示出良好的药代动力学特性和抗肿瘤功效,具有可接受的耐受性。这些结果表明,BET
    DOI:
    10.1016/j.ejmech.2021.113953
点击查看最新优质反应信息

文献信息

  • 3-(BENZOIMIDAZOL-2-YL)-INDAZOLE INHIBITORS OF THE WNT SIGNALING PATHWAY AND THERAPEUTIC USES THEREOF
    申请人:Samumed, LLC
    公开号:US20140194441A1
    公开(公告)日:2014-07-10
    Indazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an indazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease, lung disease and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.
    揭示了用于治疗各种疾病和病理的吲唑化合物。更具体地,本公开涉及使用吲唑化合物或其类似物治疗由Wnt途径信号激活所特征的疾病(例如癌症、异常细胞增殖、血管生成、阿尔茨海默病、肺部疾病和骨关节炎),调节由Wnt途径信号介导的细胞事件,以及由于Wnt途径和/或一个或多个Wnt信号组分的突变或失调而导致的遗传疾病和神经系统疾病/疾患/疾病。还提供了治疗与Wnt相关疾病状态的方法。
  • [EN] 3-(1H-BENZO[D]IMIDAZOL-2-YL)-1H-PYRAZOLO[4,3-B]PYRIDINES AND THERAPEUTIC USES THEREOF<br/>[FR] 3-(1H-BENZO[D]IMIDAZOL-2-YL)-1H-PYRAZOLO[4,3-B]PYRIDINES ET LEURS UTILISATIONS THÉRAPEUTIQUES
    申请人:SAMUMED LLC
    公开号:WO2017023989A1
    公开(公告)日:2017-02-09
    4-Azaindazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of a 4-azaindazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.
    4-氮杂吲唑化合物用于治疗各种疾病和病理已被披露。更具体地,本发明涉及使用4-氮杂吲唑化合物或其类似物,治疗由Wnt途径信号激活所特征的疾病(例如,癌症,异常细胞增殖,血管生成,纤维化疾病,骨骼或软骨疾病和骨关节炎),调节由Wnt途径信号介导的细胞事件,以及由于Wnt途径和/或一个或多个Wnt信号组分的突变或失调而导致的遗传疾病和神经病理条件/障碍/疾病。还提供了治疗与Wnt相关疾病状态的方法。
  • [EN] 3-(1H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[4,3-B]PYRIDINES AND THERAPEUTIC USES THEREOF<br/>[FR] 3-(1H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[4,3-B]PYRIDINES ET LEURS UTILISATIONS THÉRAPEUTIQUES
    申请人:SAMUMED LLC
    公开号:WO2017023972A1
    公开(公告)日:2017-02-09
    4-Azaindazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of a 4-azaindazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.
    披露了用于治疗各种疾病和病理的4-氮杂吲唑化合物。更具体地,本发明涉及使用4-氮杂吲唑化合物或其类似物,治疗由Wnt途径信号激活所特征的疾病(例如癌症、异常细胞增殖、血管生成、纤维化疾病、骨骼或软骨疾病和骨关节炎),调节由Wnt途径信号介导的细胞事件,以及由于Wnt途径和/或一个或多个Wnt信号组分的突变或失调而导致的遗传疾病和神经病理状况/障碍/疾病。还提供了治疗与Wnt相关疾病状态的方法。
  • 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF
    申请人:SAMUMED, LLC
    公开号:US20130296302A1
    公开(公告)日:2013-11-07
    Provided herein are compounds according to Formulas (I) or (II) and pharmaceutically acceptable salts thereof, and compositions comprising the same, for use in various methods, including treating cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease, lung disease, osteoarthritis, idiopathic pulmonary fibrosis and neurological conditions/disorders/diseases.
    本文提供了根据化学式(I)或(II)提供的化合物及其药学上可接受的盐,以及包含它们的组合物,用于各种方法,包括治疗癌症、异常细胞增殖、血管生成、阿尔茨海默病、肺部疾病、骨关节炎、特发性肺纤维化和神经系统疾病/紊乱/疾病。
  • [EN] SUBSTITUTED BENZIMIDAZOLE CARBOXAMIDES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS<br/>[FR] BENZIMIDAZOLE CARBOXAMIDES SUBSTITUÉS ET LEUR UTILISATION DANS LE TRAITEMENT DE TROUBLES MÉDICAUX
    申请人:BIAL BIOTECH INVEST INC
    公开号:WO2021055591A1
    公开(公告)日:2021-03-25
    The invention provides substituted benzimidazole carboxamides and related compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat a medical disorder, e.g., cancer, lysosomal storage disorder, neurodegenerative disorder, inflammatory disorder, in a patient.
    这项发明提供了替代苯并咪唑羧酰胺及相关化合物,含有这些化合物的组合物,医疗工具包,以及使用这些化合物和组合物治疗患者的医疗疾病的方法,例如癌症、溶酶体贮积症、神经退行性疾病、炎症性疾病。
查看更多